G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Director – GI/Liver Biomarkers & Translational Research

Biology & BiotechPosted on Nov 7
Full-timeFoster City, CA, USA

About the Job

Requirements

  • A PhD, MD, MD/PhD, PharmD, or equivalent advanced degree in immunology, gastroenterology, hepatology, inflammation biology, translational medicine, pharmacology, or a related discipline.
  • Typically 12 or more years of relevant biotechnology, pharmaceutical, clinical development, or human translational research experience, including substantial leadership of clinical-stage biomarker programs.
  • Demonstrated ownership of biomarker and translational strategy across multiple complex programs, with examples of influencing dose, proof-of-concept, patient population, go/no-go, regulatory, or portfolio decisions.
  • Recognized scientific expertise in human immunology and immune-mediated inflammatory disease, with strong GI/IBD expertise and meaningful knowledge of liver inflammation, injury, or fibrosis.
  • Proven and sustained scientific productivity and innovation, demonstrated by impactful peer-reviewed publications, patents, influential translational or clinical datasets, invited presentations, external recognition, major development milestones, or comparable achievements.
  • Extensive experience with biomarker-rich clinical trials, regulated development, assay externalization, clinical sample operations, complex data integration, and regulatory documentation or interactions.
  • Demonstrated ability to lead and influence senior stakeholders, independently structure multiple large-scale assignments, manage resources, and communicate cohesive strategy to governance and executive audiences.
  • Track record of mentoring and developing scientists and elevating standards across cross-functional or matrix teams.

Responsibilities

  • Own and continuously evolve the integrated GI/IBD and liver biomarker and translational strategy across multiple clinical-stage assets, aligning evidence generation with disease-area, asset, regulatory, and portfolio objectives.
  • Lead the most complex programs from early clinical development through Phase II/III, defining decision criteria for target engagement, dose, proof-of-concept, patient selection, response, safety, differentiation, and lifecycle opportunities.
  • Provide hands-on scientific leadership for analysis and interpretation of blood, stool, intestinal and liver tissue, endoscopic, histologic, imaging, pathology, and multi-omic datasets.
  • Create cross-asset frameworks for forward and reverse translation, including integrated biopsy strategies and analyses of response, resistance, relapse, patient heterogeneity, and mechanisms of action.
  • Lead biomarker and translational contributions to protocols, analysis plans, investigator brochures, clinical study reports, briefing documents, regulatory submissions, and health authority interactions.
  • Partner with senior leaders across Clinical Development, Research, Clinical Pharmacology, Biostatistics, Bioinformatics, Diagnostics, Clinical Operations, and Regulatory; articulate scientific opportunities, uncertainties, trade-offs, and recommendations.
  • Oversee biomarker execution, assay and vendor strategy, budgets, timelines, resources, and delivery across several concurrent studies; anticipate risks and establish mitigation plans.
  • Establish collaborations with investigators, KOLs, pathologists, consortia, and technology partners; represent GI/liver biomarker science at advisory boards, scientific meetings, and external forums.
  • Lead publication and evidence-dissemination strategy and maintain an active external scientific presence that strengthens the credibility and differentiation of the portfolio.
  • Develop direct reports and matrix team members, elevate scientific and operational standards, and build reusable capabilities, analytics, and best practices across the biomarker organization.
  • Contribute to portfolio prioritization, resource planning, and long-range capability strategy; present clear business and scientific cases to governance and executive audiences.

Desired Qualifications

  • Direct leadership of biomarker strategies in Crohn’s disease and/or ulcerative colitis, including endoscopic, histologic, intestinal tissue, blood, and stool assessments.
  • Experience in liver inflammation, fibrosis, noninvasive biomarkers, imaging, and/or liver histopathology.
  • Experience spanning first-in-human through registrational development and direct participation in FDA, EMA, or other health authority interactions.
  • Expertise integrating single-cell, spatial, transcriptomic, proteomic, cellular, genetic, pathology, imaging, and clinical data into portfolio decisions.
  • Knowledge of companion diagnostic strategy and evidence requirements.
  • Established relationships with investigators, KOLs, consortia, or technology innovators in GI/IBD, liver disease, or human translational immunology.

About the Company

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company size
10,001+
Company stage
IPO
Headquarters
Foster City, CA
Founded
1987

Recently Posted Jobs

Explore more opportunities at Gilead Sciences

See more jobs